SCHEMBL4326568

SCHEMBL4326568

Cn1c(CBr)c(Cl)c(=O)n1-c1ccc(F)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 2/20 0.44
KMT2A Q03164 3/20 0.41
KAT2B Q92831 2/20 0.40
PIN1 Q13526 1/20 0.40
MEN1 O00255 2/20 0.40
GAA P10253 2/20 0.40
PHOSPHO1 Q8TCT1 1/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
EGFR P00533 1/20 0.37
HTT P42858 2/20 0.36
KCNH2 Q12809 2/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325141 0.84 MEN1 (0.38) KMT2AKAT2BMEN1GAAMAPT
SCHEMBL4334363 0.84 FPR2 (0.41) KMT2AMEN1GAAMAPTCYP1A2
SCHEMBL4322495 0.80 BRD9 (0.45) BRD9KMT2AKAT2BPIN1MEN1
SCHEMBL4321221 0.78 BCHE (0.45) KMT2AMEN1GAACYP1A2POLB
SCHEMBL4335745 0.78 FPR2 (0.38) PHOSPHO1MAPTHTTALDH1A1LMNA
SCHEMBL4318691 0.78 PDE7A (0.32) BRD9
SCHEMBL4326755 0.76 ALDH1A1 (0.46) KMT2AGAAMAPTPOLBHPGD
SCHEMBL4326943 0.75 NPBWR1 (0.41) POLBALDH1A1
SCHEMBL5264271 0.73 MEN1 (0.36) KMT2AKAT2BMEN1GAAMAPT
SCHEMBL4334558 0.73 ALDH1A1 (0.51) KMT2AGAAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders GRIN1, GRM1, GRIN3A BRD9 3795/4885KMT2A 2407/4885KAT2B 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.